GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Piotroski F-Score

Sanara MedTech (Sanara MedTech) Piotroski F-Score : 3 (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sanara MedTech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Sanara MedTech's Piotroski F-Score or its related term are showing as below:

SMTI' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Sanara MedTech was 7. The lowest was 2. And the median was 4.


Sanara MedTech Piotroski F-Score Historical Data

The historical data trend for Sanara MedTech's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Piotroski F-Score Chart

Sanara MedTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 5.00 2.00 3.00

Sanara MedTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 3.00

Competitive Comparison of Sanara MedTech's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, Sanara MedTech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanara MedTech's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -1.828 + -1.06 + -0.237 + -1.764 = $-4.89 Mil.
Cash Flow from Operations was -1.72 + 1.064 + -0.849 + -1.594 = $-3.10 Mil.
Revenue was 15.753 + 16.025 + 17.69 + 18.537 = $68.01 Mil.
Gross Profit was 13.566 + 14.274 + 15.902 + 16.647 = $60.39 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(59.967 + 58.279 + 75.474 + 73.871 + 70.912) / 5 = $67.7006 Mil.
Total Assets at the begining of this year (Mar23) was $59.97 Mil.
Long-Term Debt & Capital Lease Obligation was $10.39 Mil.
Total Current Assets was $17.19 Mil.
Total Current Liabilities was $12.75 Mil.
Net Income was 0.769 + -1.47 + -4.107 + -1.178 = $-5.99 Mil.

Revenue was 9.671 + 13.045 + 15.316 + 15.522 = $53.55 Mil.
Gross Profit was 8.713 + 10.816 + 12.947 + 13.396 = $45.87 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(33.934 + 46.478 + 61.477 + 61.035 + 59.967) / 5 = $52.5782 Mil.
Total Assets at the begining of last year (Mar22) was $33.93 Mil.
Long-Term Debt & Capital Lease Obligation was $1.86 Mil.
Total Current Assets was $19.01 Mil.
Total Current Liabilities was $10.60 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sanara MedTech's current Net Income (TTM) was -4.89. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sanara MedTech's current Cash Flow from Operations (TTM) was -3.10. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=-4.889/59.967
=-0.08152817

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-5.986/33.934
=-0.17640125

Sanara MedTech's return on assets of this year was -0.08152817. Sanara MedTech's return on assets of last year was -0.17640125. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sanara MedTech's current Net Income (TTM) was -4.89. Sanara MedTech's current Cash Flow from Operations (TTM) was -3.10. ==> -3.10 > -4.89 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=10.394/67.7006
=0.15352892

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=1.859/52.5782
=0.03535686

Sanara MedTech's gearing of this year was 0.15352892. Sanara MedTech's gearing of last year was 0.03535686. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=17.187/12.746
=1.34842303

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=19.008/10.602
=1.79286927

Sanara MedTech's current ratio of this year was 1.34842303. Sanara MedTech's current ratio of last year was 1.79286927. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sanara MedTech's number of shares in issue this year was 8.42. Sanara MedTech's number of shares in issue last year was 8.174. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=60.389/68.005
=0.88800823

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=45.872/53.554
=0.856556

Sanara MedTech's gross margin of this year was 0.88800823. Sanara MedTech's gross margin of last year was 0.856556. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=68.005/59.967
=1.13404039

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=53.554/33.934
=1.57818118

Sanara MedTech's asset turnover of this year was 1.13404039. Sanara MedTech's asset turnover of last year was 1.57818118. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sanara MedTech has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Sanara MedTech  (NAS:SMTI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sanara MedTech Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanara MedTech (Sanara MedTech) Business Description

Traded in Other Exchanges
N/A
Address
1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.
Executives
Eric D Major director 751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming officer: President - Surgical Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman officer: President - Wound Care Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon officer: President - R&D 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein director 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger director 1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison officer: President - Telehealth Svcs. 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena director, officer: Principal Executive Officer 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil officer: Chief Financial Officer 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc. 10 percent owner 1375 ENCLAVE PARKWAY, HOUSTON TX 77077